-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $32

Benzinga·05/08/2026 20:43:19
Listen to the news
Citigroup analyst Yigal Nochomovitz maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $33 to $32.